Abstract Body

HIV has proved a daunting target for vaccine development, foiling efforts to generate cellular and humoral responses capable of targeting viral vulnerabilities. While decades of research have demonstrated the critical role of CD8+ T cells in containing viral infections, the ability to elicit HIV-protective T cell responses with conventional approaches has remained frustratingly elusive. Nearly all T cell-based vaccine regimens tested to date have used non-persistent vectors, which engender predominantly central memory T cell (TCM) responses. In the case of HIV infection, vaccine-induced TCM CD8+ T cell responses are at a kinetic disadvantage to the rapid pace of viral replication, thus giving rise to a scenario of an anamnestic immune response that arrives at the site of infection ‘too late’ with ‘too little’ magnitude to prevent irreversible establishment of the persistent viral reservoir. In contrast, accumulating evidence supports a protective role for effector memory T cell (TEM) responses, which are fully differentiated memory T cells located directly at portals of pathogen entry, able to respond to pathogens orders of magnitude more quickly than TCM responses. Here, we present evidence for the early vulnerability of HIV to cellular immunity and discuss the rationale for inclusion of CD8+ TEM responses in prophylactic HIV vaccine design.